IncyteMEX:INCY 84 OCF Yield % is 6.62 as of Jun. 30, 2026, which is 102% above its 10-year median of 3.27. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,452.53 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Incyte ranks better than 92.73% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Incyte OCF Yield % Related Terms
Incyte OCF Yield % Historical Data
* Premium members only.
The historical data trend for Incyte's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INCY vs INSM, BNTX, ROIV: OCF Yield % Comparison
For the Biotechnology subindustry, Incyte's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Incyte's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (MEX:INCY) has a OCF Yield % of 6.62 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Incyte and its competitors. This is 102% above median its historical median of 3.27. According to the industry distribution chart, Incyte ranks #103 out of 1416 companies in the Biotechnology industry, placing it in the top 7.3%.
Is Incyte's OCF Yield % too high?
Incyte's current OCF Yield % of 6.62 is 102% above median its 10-year median of 3.27. Based on the distribution chart, Incyte ranks #103 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's OCF Yield % compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #103 out of 1416 companies for OCF Yield %. This places Incyte in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Incyte and its competitors. Incyte's current OCF Yield % is 6.62, which is 102% above median its own 10-year median of 3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,452.53, compared to a current price of MXN1,676.03 — trading 15.4% above its estimated fair value. The current OCF Yield % is 6.62, which is 102% above median its 10-year median of 3.27. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Incyte (MEX:INCY), the current OCF Yield % is 6.62 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN1,676.03 is trading 15.4% above its estimated GF Value™ of MXN1,452.53.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
OCF Yield %: 6.62 (102% above median its 10-year median of 3.27)
GF Value™: MXN1,452.53 vs. price of MXN1,676.03 (15.4% above fair value)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score
Get the complete analysis for MEX:INCY
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
